Baseline characteristics of all individuals with MBL or Rai 0 CLL
| Characteristic . | MBL (N = 415) . | CLL (N = 554) . | Total (N = 969) . | |
|---|---|---|---|---|
| Median age, y (range) | 65 (41-87) | 63 (31-91) | 64 (31-91) | |
| Males | 263 (63.4%) | 368 (66.4%) | 631 (65.1%) | |
| Median absolute lymphocyte count, ×109/L (range) | 6.2 (0.9-11.8) | 14.8 (5.5-280.7) | 9.7 (0.9-280.7) | |
| Median absolute clonal B-cell count, ×109/L (range) | 2.9 (0.03-4.9) | 9.3 (5.0-172.0) | 5.7 (0.03-172.0) | |
| IGHV mutation status | ||||
| Mutated | 298 (71.8%) | 355 (64.3%) | 653 (67.5%) | |
| Unmutated | 117 (28.2%) | 197 (35.7%) | 314 (32.5%) | |
| Median serum β-2 microglobulin (μg/mL) | 2.1 (0.9-21.5) | 2.2 (0.2-15.8) | 2.2 (0.2-21.5) | |
| CLL FISH* | ||||
| Low risk (del13q) | 186 (45.3%) | 288 (52.7%) | 474 (49.5%) | |
| Intermediate risk (trisomy 12 or negative) | 193 (47.0%) | 203 (37.2%) | 396 (41.4%) | |
| High risk (del11q or del17p) | 32 (7.8%) | 55 (10.1%) | 87 (9.1%) | |
| TP53 disruption (either by del17p FISH or TP53 mutation) | 20 (4.8%) | 26 (4.7%) | 46 (4.7%) | |
| CD49d ≥30% | 127 (31.8%) | 107 (21.2%) | 234 (25.9%) | |
| CD38 ≥20% | 88 (21.3%) | 114 (20.8%) | 202 (21.0%) | |
| CLL-IPI | ||||
| Low risk | 258 (62.2%) | 308 (55.6%) | 566 (58.4%) | |
| Intermediate risk | 116 (28.0%) | 188 (33.9%) | 304 (31.4%) | |
| High risk | 37 (8.9%) | 47 (8.5%) | 84 (8.7%) | |
| Very high risk | 4 (1.0%) | 11 (2.0%) | 15 (1.5%) | |
| Characteristic . | MBL (N = 415) . | CLL (N = 554) . | Total (N = 969) . | |
|---|---|---|---|---|
| Median age, y (range) | 65 (41-87) | 63 (31-91) | 64 (31-91) | |
| Males | 263 (63.4%) | 368 (66.4%) | 631 (65.1%) | |
| Median absolute lymphocyte count, ×109/L (range) | 6.2 (0.9-11.8) | 14.8 (5.5-280.7) | 9.7 (0.9-280.7) | |
| Median absolute clonal B-cell count, ×109/L (range) | 2.9 (0.03-4.9) | 9.3 (5.0-172.0) | 5.7 (0.03-172.0) | |
| IGHV mutation status | ||||
| Mutated | 298 (71.8%) | 355 (64.3%) | 653 (67.5%) | |
| Unmutated | 117 (28.2%) | 197 (35.7%) | 314 (32.5%) | |
| Median serum β-2 microglobulin (μg/mL) | 2.1 (0.9-21.5) | 2.2 (0.2-15.8) | 2.2 (0.2-21.5) | |
| CLL FISH* | ||||
| Low risk (del13q) | 186 (45.3%) | 288 (52.7%) | 474 (49.5%) | |
| Intermediate risk (trisomy 12 or negative) | 193 (47.0%) | 203 (37.2%) | 396 (41.4%) | |
| High risk (del11q or del17p) | 32 (7.8%) | 55 (10.1%) | 87 (9.1%) | |
| TP53 disruption (either by del17p FISH or TP53 mutation) | 20 (4.8%) | 26 (4.7%) | 46 (4.7%) | |
| CD49d ≥30% | 127 (31.8%) | 107 (21.2%) | 234 (25.9%) | |
| CD38 ≥20% | 88 (21.3%) | 114 (20.8%) | 202 (21.0%) | |
| CLL-IPI | ||||
| Low risk | 258 (62.2%) | 308 (55.6%) | 566 (58.4%) | |
| Intermediate risk | 116 (28.0%) | 188 (33.9%) | 304 (31.4%) | |
| High risk | 37 (8.9%) | 47 (8.5%) | 84 (8.7%) | |
| Very high risk | 4 (1.0%) | 11 (2.0%) | 15 (1.5%) | |
Eleven individuals (3 with MBL and 8 with Rai 0 CLL) have other findings on FISH studies, including 3 individuals who had del6q (1 MBL, 2 CLL) and 8 individuals with del14q (2 MBL, 6 CLL).